Table 2.
Patient Characteristics Used in the Analysis
| Group A | Group B | |
|---|---|---|
| Gender (%) | ||
| All | 528 (100%) | 43 (100%) |
| Male | 314 (59.5%) | 25 (58.14%) |
| Female | 214 (40.5%) | 18 (41.86%) |
| Age (SD) | ||
| All | 61.54 (11.84) | 58.04 (12.51) |
| Male | 63.35 (11.14) | 60.86 (10.86) |
| Female | 58.88 (12.35) | 54.12 (13.94) |
| BMI | ||
| All | 25.05 (3.45) | 25.67 (3.54) |
| Male | 25.48 (3.36) | 26.48 (2.49) |
| Female | 24.42 (3.47) | 24.53 (4.45) |
| Number of Cycles (SD) | ||
| All | 8.47 (3.66) | 7.95 (4.55) |
| Male | 8.60 (3.63) | 8.08 (4.41) |
| Female | 8.16 (3.74) | 7.77 (4.85) |
| Interruption (%) | ||
| All | 115 (21.78%) | 17 (39.53%) |
| Male | 64 (12.12%) | 9 (20.93%) |
| Female | 51 (9.66%) | 8 (18.6%) |
| Tumor response (%) | ||
| Complete Response | 18 (3.41%) | 1 (2.33%) |
| Partial Response | 77 (14.58%) | 8 (18.60%) |
| Steady Disease | 65 (12.31%) | 5 (11.63%) |
| Progress Disease | 73 (13.64%) | 1 (2.33%) |
| Non-Evaluated | 295 (55.87%) | 26 (60.47%) |
Group A (DPYD variants non-carriers), group B (carriers of any DPYD variants among DPYD c.2846A>T, DPYD∗2A, and DPYD∗13 and DPYD-HapB3). SD, standard deviation.